ADMA Biologics Inc

ADMA remains in a Stage 3 distribution phase with price below declining EMAs and failed rally attempts. The medium-term bias is bearish, favoring sell-side engagement on rallies into the 9/20 EMA zone. Short-term consolidation around flat EMAs offers no clear timing edge, so we defer execution (Trim) until price confirms rejection at the resistance area.

• ↑Ascentive drove total revenue to $124.4M (+2% YoY) with 24% growth
• ↑Gross margin rose to 69% (from 55%), and adjusted EBITDA climbed 22% to $61.8M
• ↓Increased supply and pricing pressure may compress immunoglobulin margins